AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06311929
Drug: PD-1 monoclonal antibody and lenvatinib
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patient receives first adjuvant PD-1 monoclonal antibody 2-4 weeks postoperatively, 200 mg IV, every 21 days for a total of 9 cycles; lenvatinib is initiated orally 2-4 weeks postoperatively for 6 months.
Trial: NCT06311929
Drug: PD-1 monoclonal antibody
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient receives first adjuvant PD-1 monoclonal antibody 2-4 weeks postoperatively, 200mg IV over 21 days for 9 cycles.
Trial: NCT05661591
Drug: Fluconazole Capsules
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SHR2554 Tablets+ Fluconazole Capsules
Trial: NCT06628622
Drug: BI 1356225
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1356225
Trial: NCT04941131
Drug: Chlorhexidine digluconate, povidone iodine
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This is a mouth wash that can be used over the counter.
Trial: NCT05849467
Drug: 89 Zr-Df-crefmirlimab
RxNorm normalized name: CEMIPLIMAB
DrugBank: Crefmirlimab (DB17577)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: an 80 kDa minibody (Mb) with high~affinity to CD8 glycoprotein (binding EC50 = 0.4 nM) that is conjugated with deferoxamine (Df)~and radiolabeled with the positron emitting radionuclide, Zr-89 (T1/2 78.4 hours).
Trial: NCT05774665
Drug: Omega 3
RxNorm normalized name: omega 3,6
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acid enriched for eicosapentaenoic acid (EPA)
Trial: NCT05192681
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab in combination with docetaxel until the development of PD, unacceptable toxicities, withdrawal of informed consent, end of study, lost to follow-up, or death, whichever occurs first.
Trial: NCT06003933
Drug: Bupivacaine Hydrochloride
RxNorm normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 ml of 0.25% bupivacaine on each side of cervical region at C5
Trial: NCT06003933
Drug: Lidocaine Hydrochloride
RxNorm normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10ml xylocaine on each side of cervical region at C5
Trial: NCT05730920
Drug: Methadone
RxNorm normalized name: Methadone
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV Methadone
Trial: NCT05730920
Drug: Liposomal bupivacaine (LB, Exparel)
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LB and bupivacaine hydrochloride via erector spinae plane blocks
Trial: NCT05408663
Drug: EXT608
RxNorm normalized name: EXT608
DrugBank: EXT608 (DB18453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EXT608 is an investigational drug administered via subcutaneous injection
Trial: NCT05948072
Drug: mFOLFOX6 + Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab + mFOLFOX6: Cetuximab (500mg/m2 IV ) will be given. Oxaliplatin (85 mg/m2 IV over 2 h on day 1), Leucovorin calcium (350 mg/m2 IV over 2 h on day 1) plus a bolus of 5FU (400 mg/m2) followed by a 46h-48h IV infusion of 5FU 2400 mg/m2 will be repeated for every 2 weeks. The regimens repeat every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
Trial: NCT06050915
Drug: DISC-3405
RxNorm normalized name: xylitol
DrugBank: Xylitol (DB11195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DISC-3405 is administered as a single dose IV infusion or subcutaneous injection
Trial: NCT05768490
Drug: Almonertinib
RxNorm normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: almonertinib po 110mg QD
Trial: NCT06050915
Drug: DISC-3405
RxNorm normalized name: xylitol
DrugBank: Xylitol (DB11195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DISC-3405 is administered in multiple ascending doses as an IV infusion or subcutaneous injection
Trial: NCT06079879
Drug: Bomedemstat
RxNorm normalized name: Bomedemstat
DrugBank: Bomedemstat (DB17234)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Capsule
Trial: NCT06079879
Drug: Anagrelide
RxNorm normalized name: anagrelide
DrugBank: Anagrelide (DB00261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral Capsule
Trial: NCT06079879
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral Tablet
Trial: NCT06079879
Drug: Interferon alfa/pegylated interferon alfa
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Solution
Trial: NCT06079879
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT05627154
Drug: Citalopram
RxNorm normalized name: Citalopram
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Serotonin-reuptake inhibitor commonly used to treat depressive and anxiety disorders.
Trial: NCT05315713
Drug: Mosunetuzumab SC
RxNorm normalized name: Mosunetuzumab
DrugBank: Mosunetuzumab (DB15434)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive SC mosunetuzumab for up to 17 treatment cycles (cycle length = 21 days)
Trial: NCT05315713
Drug: Tiragolumab
RxNorm normalized name: Tiragolumab
DrugBank: Tiragolumab (DB16409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive IV tiragolumab every 3 weeks (Q3W) for up to 17 treatment cycles (cycle length = 21 days)
Trial: NCT05315713
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive IV atezolizumab Q3W for up to 17 treatment cycles (cycle length = 21 days)
Trial: NCT05173792
Drug: AK119
RxNorm normalized name: AK119
DrugBank: AK119 (DB16423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive AK119 intravenously.
Trial: NCT06532656
Drug: Lenacapavir
RxNorm normalized name: Lenacapavir
DrugBank: Lenacapavir (DB15673)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally without regard to food
Trial: NCT05963217
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Fludarabine (for 3 days) will be administered as conditioning before cell infusion with TBI-2001.
Trial: NCT06022588
Drug: Sodium butyrate, 1-13C, 99%, Cambridge Isotope Laboratories, Inc.USA
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a solution containing butyrate of which 12C of the last 4 carbon positions of butyrate were replaced by 13C butyrate. Participants received 0.80 gram 13C-butyrate (7.3 mMol butyrate / 29 mMol 13C) dissolved in 50 mL water at baseline
Trial: NCT04830267
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab 200mg IV starting day 1 and then every 2 weeks thereafter. Treatment with Camrelizumab will continue until progression or unacceptable toxicity.
Trial: NCT04205539
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: This medication will be administered sublingually using an LMA Intranasal Mucosal Atomization Device, which allows the medication to be administered in the form of a spray. Patients will be instructed to keep the medication in their mouth for about 2 minutes, or until fully absorbed. Pulse oximetry and blood pressure will be monitored throughout the duration of treatment. After the subject is asleep, the second DTI scan will be done.
Trial: NCT04750239
Drug: Nivatrotamab
RxNorm normalized name: Nivatrotamab
DrugBank: Nivatrotamab (DB16654)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti GD2×CD3 monoclonal bi-specific antibody
Trial: NCT04582916
Drug: 11C-MCI
RxNorm normalized name: 11C-choline
DrugBank: Choline C 11 (DB09277)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injected IV followed by PET scanning
Trial: NCT06249113
Drug: Adjuvant lidocaine continous
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjuvant lidocaine continous intravenous on tumor craniotomy surgery
Trial: NCT06559280
Drug: esketamine
RxNorm normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: During the operation, 0.25mg/kg esketamine was induced, and 1mg/kg esketamine was added to the postoperative analgesia pump
Trial: NCT06283888
Drug: CYP2C19 Genotype Guided DAPT
RxNorm normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with \*2 or \*3 carrier will be received ticagrelor 60mg or 45mg bid (if \<50 kg, ≥75 years) + aspirin 100 mg qd; Patients with \*2 or \*3 non-carrier will be received clopidogrel 75mg qd + aspirin 100 mg qd
Trial: NCT06283888
Drug: Conventional DAPT
RxNorm normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be conventionally received ticagrelor 90mg bid or clopidogrel 75mg qd + aspirin 100 mg qd
Trial: NCT06095596
Drug: Upadacitinib
RxNorm normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral upadacitinib 45mg/d for 8 weeks in the induction therapy.
Trial: NCT06095596
Drug: Vedolizumab
RxNorm normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Vedolizumab 300mg intravenously on weeks 1, 2, 6, and then on every 8-week interval.
Trial: NCT04705584
Drug: CycloSPORINE Ophthalmic Suspension
RxNorm normalized name: cyclosporine Ophthalmic Suspension
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This treatment arm includes the use of topical cyclosporine A after 2 weeks of topical steroid use.
Trial: NCT04705584
Drug: LTacrolimus Topical
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This treatment arm includes the use of topical Tacrolimus after 2 weeks of topical steroid use.
Trial: NCT05187884
Drug: Darovasertib
RxNorm normalized name: Darovasertib
DrugBank: Darovasertib (DB16059)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Darovasertib 300 mg tablets twice daily
Trial: NCT05179226
Drug: Ferric Derisomaltose
RxNorm normalized name: ferric derisomaltose
DrugBank: Ferric derisomaltose (DB15617)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will be treated with Ferric derisomaltose 20 mg/kg at baseline visit except for 12 subjects included in the PK-group, who will be treated with 10 mg/kg
Trial: NCT00001105
Drug: F105 Monoclonal Antibody (Human)
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00002096
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002096
Drug: Didanosine
RxNorm normalized name: Didanosine
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002096
Drug: Ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05646316
Drug: Indocyanine Green Solution
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given via injection
Trial: NCT05604599
Drug: Intranasal dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 45 -60 min before the operation, patients will receive dose of dexmedetomidine 1microgram/kg diluted in 10ml 0.9% saline administered to each naris as drops + infusion saline
Trial: NCT05604599
Drug: Intravenous dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patients will receive loading dose of dexmedetomidine 1 µg/kg diluted in 10ml 0.9% saline infused over 45- 60 min before induction of anesthesia, followed by continuous infusion of (0.4 µ g/kg/h) + intranasal saline.
Trial: NCT05902000
Drug: Dual antiplatelet treatment
RxNorm normalized name: Tums Dual Action
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy is administered after 24 hours of imaging follow-up excluding intracranial hemorrhagic complications. Aspirin Enteric-coated Tablets (Bay Aspirin) 100mg once a night+Clopidogrel Sulfate Tablets (Plavix) 75mg once daily. If there is no contraindication, maintain for more than 1 month, then adjust the dosing regimen according to the guidelines.
Trial: NCT05633810
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg non-enteric-coated tablet taken twice daily.
Trial: NCT05633810
Drug: Colchicine
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 mg tablet taken once daily
Trial: NCT05633810
Drug: Colchicine Placebo
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablet taken once daily.
Trial: NCT06269445
Drug: Icaritin Combined With Bevacizumab and FOLFIRI
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab and FOLFIRI are second-line treatment options for colorectal cancer; synergistic efficacy expected in combination with Icaritin
Trial: NCT00245739
Drug: TMC-114
RxNorm normalized name: crizanlizumab-tmca
DrugBank: MC-1 (DB05315)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600/100 mg tablets of TMC114/rtv BID until commercial available to the subject
Trial: NCT06404463
Drug: QL1706 (bispecific antibody targeting PD-1 and CLTA-4)
RxNorm normalized name: QL1706
DrugBank: QL1706 (DB17562)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QL1706 is a novel bispecific combination antibody composed of a recombinant humanized IgG4 monoclonal antibody targeting human PD-1 (programmed cell death protein 1) (PSB103) and a recombinant humanized IgG1 monoclonal antibody targeting human CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) (PSB105). Both antibodies have undergone engineering modifications to introduce mutations facilitating their correct assembly and preventing mispairing, and are expressed in the same cell line at a predetermined ratio (approximately 2:1).
Trial: NCT06404463
Drug: Albumin-bound paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Albumin-bound paclitaxel improves the solubility and delivery of paclitaxel to tumor cells by binding to human albumin, facilitating its transportation through the bloodstream and enhancing its uptake into tumor tissue. It works by binding to and stabilizing microtubules within cancer cells, thereby disrupting the normal process of cell division and leading to cell cycle arrest and apoptosis, ultimately resulting in the death of cancer cells.
Trial: NCT06404463
Drug: Epirubicin
RxNorm normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epirubicin, a chemotherapy medication, is part of the anthracycline class and is used in the treatment of various cancers, including breast cancer, ovarian cancer, and soft tissue sarcoma. It functions by interfering with DNA replication and RNA synthesis within cancer cells, ultimately leading to cell death. Despite its efficacy, epirubicin can cause side effects such as nausea, hair loss, and bone marrow suppression.
Trial: NCT04295486
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-enteric coated 81 mg Aspirin tablet.
Trial: NCT06668792
Drug: BCD-248
RxNorm normalized name: anacaulase-bcdb
DrugBank: Anacaulase (DB17449)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneously
Trial: NCT06237231
Drug: DIPYRONE
RxNorm normalized name: Dipyrone
DrugBank: Metamizole (DB04817)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyrone tablet 1.000mg
Trial: NCT06237231
Drug: TRAMADOL
RxNorm normalized name: Tramadol
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tramadol tablet 50mg
Trial: NCT06237231
Drug: Dipyrone Placebo
RxNorm normalized name: dipyrone
DrugBank: Metamizole (DB04817)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyrone placebo tablet
Trial: NCT06237231
Drug: Tramadol Placebo
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tramadol placebo capsule
Trial: NCT04608448
Drug: Rapamycin Topical Ointment
RxNorm normalized name: natamycin Topical Cream
DrugBank: Natamycin (DB00826)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8% topical rapamycin ointment
Trial: NCT04882540
Drug: brivaracetam
RxNorm normalized name: Brivaracetam
DrugBank: Brivaracetam (DB05541)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: * Pharmaceutical form: Film-coated tablets~* Concentration: 100 mg tablets~* Route of administration: Oral use
Trial: NCT06334094
Drug: Ozanimod
RxNorm normalized name: Ozanimod
DrugBank: Ozanimod (DB12612)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A hard capsule that is taken daily for one year.
Trial: NCT04706637
Drug: Evogliptin
RxNorm normalized name: Evogliptin
DrugBank: Evogliptin (DB12625)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: evogliptin 5mg + metformin, oral administration once a day for 48 weeks
Trial: NCT04706637
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: dapagliflozin 10mg + metformin, oral administration once a day for 48 weeks
Trial: NCT05614453
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab is an investigational, humanised-IgG4 monoclonal antibody with high affinity/binding specificity for PD-1. It is engineered to minimise binding to FcγR on macrophages to abrogate antibody-dependent cellular phagocytosis.
Trial: NCT05614453
Drug: Sitravatinib
RxNorm normalized name: Sitravatinib
DrugBank: Sitravatinib (DB15036)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitravatinib is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with potential anti-neoplastic activity.
Trial: NCT05283954
Drug: Combination regimen: Albendazole, Vitamin C
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive the following treatments:~Vitamin C 50 mg oral tablets: One tablet right after randomization (Day 0) followed by one daily tablet for the following 09 days.~Albendazole 200 mg oral tablets: One tablet right after randomization (Day 0) followed by one daily tablet for the following 04 days.~Vitamin C 50 mg oral tablets: Tablets started right after randomization (Day 0; 130mcg/ kg dosing), administered once a day for 05 consecutive days.
Trial: NCT00334399
Drug: Miglitol
RxNorm normalized name: Miglitol
DrugBank: Miglitol (DB00491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06007729
Drug: HS-20093
RxNorm normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in all subjucts will receive HS-20093 at 10mg/kg
Trial: NCT06339424
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab 1200 mg will be administered as an IV infusion on Day 1 of each cycle, with cycles occurring every 3 weeks. The initial dose will be delivered over 60 (± 15) minutes, and if well-tolerated, subsequent infusions may be given over 30 minutes. For patients who achieve a complete response (CR) within one year of treatment, atezolizumab should be continuously used for a year. For patients who experience a partial response (PR), atezolizumab should be continued until achieving CR or experiencing progressive disease (PD). Patients with stable disease should receive atezolizumab for 6 months. In the case of PD, atezolizumab should be discontinued at the time when PD is confirmed.
Trial: NCT06339424
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 15 mg/kg will be administered as an IV infusion on Day 1 of each 3-week cycle. The initial dose will be delivered over 90 minutes (±15 minutes), and if well-tolerated, subsequent infusions may be given over 60 minutes. For patients who achieve a complete response (CR) within one year of treatment, bevacizumab should be continuously used for a year. In the case of patients experiencing a partial response (PR), bevacizumab should be continued until achieving CR or experiencing progressive disease (PD). Patients with stable disease should receive bevacizumab for 6 months. In the event of PD, bevacizumab should be discontinued when PD is confirmed. Temporary withholding or dose reduction of bevacizumab is permitted if patients experience adverse events such as bleeding episodes, severe hypertension, or proteinuria at the discretion of the treating physician.
Trial: NCT05623592
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium chloride subcutaneously
Trial: NCT05323149
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Giving TXA (loading dose of 1gm of TXA, followed by a 1gm of maintenance dose over 8 hours for 48 h).
Trial: NCT05744739
Drug: Tomivosertib
RxNorm normalized name: Tomivosertib
DrugBank: Tomivosertib (DB15219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05269290
Drug: Ingavirin®, syrup, 30 mg/5 ml
DrugBank: Ingavirin (DB11944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A dose will be based on the body weight; Ingavirin® will be administered once a day on top of standard therapy.